The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kraj, P.
Right arrow Articles by Ignatowicz, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kraj, P.
Right arrow Articles by Ignatowicz, L.
The Journal of Immunology, 2001, 166: 2251-2259.
Copyright © 2001 by The American Association of Immunologists

{alpha}{beta}TCRs Differ in the Degree of Their Specificity for the Positively Selecting MHC/Peptide Ligand1

Piotr Kraj, Rafal Pacholczyk and Leszek Ignatowicz2

Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta, GA 30912 Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta, GA 30912


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
We have tested the peptide specificity of positive selection using three transgenic {alpha}{beta}TCRs, originally selected on class II MHC (Ab) covalently bound with one peptide E{alpha} (52–68) (Ep). The transgenic TCR specific for the cytochrome c-derived (43–58) peptide was selected on Ab bound with different arrays of endogenous peptides or the analogue of Ep covalently bound to Ab, but not on the original AbEp complex. In contrast, transgenic TCRs specific for two different analogues of the Ep peptide and Ab did not mature as CD4+ T cells in various thymic environments, including the AbEpIi- mice. These results show that TCRs can be promiscuous or specific for the selecting MHC/peptide complex, and suggest that in mice described in this study transgenic expression of the TCR changes the original requirements for the positively selecting MHC/peptide complex. Future studies will determine whether the latter phenomenon is general or specific for this system.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
The majority of T lymphocytes develop in the thymus, where their receptors for Ags ({alpha}{beta}TCRs) confront multiple MHC/peptide complexes present on thymic stromal cells. TCRs are inherently biased to recognize MHC and can discriminate between peptides bound to MHC within a wide range of avidity (1, 2, 3, 4). Low-avidity interactions between TCRs on immature T cells and self MHC/peptide ligand(s) result in positive selection, which rescues selected thymocytes from programmed cell death (5, 6). High-avidity interactions between TCRs and self MHC/peptide complex(es) have an opposite outcome, i.e., the thymocyte is classified as self-reactive and is induced to die during negative selection (7, 8). The lack of recognition of self MHC/peptide complexes by immature thymocytes allows programmed cell death to occur and neglected immature T cells to die (9). While the specificity of negative selection for a defined MHC/peptide has been shown in multiple experiments, the contribution of self peptide(s) presented by MHC during positive selection of T cells is less known. Using mice deficient in intracellular chaperones involved in Ag processing, it was demonstrated that efficient positive selection of a wide repertoire of {alpha}{beta}TCRs expressed on T cells requires many different peptides to be associated with MHC molecules (10, 11, 12, 13, 14). However, a noticeable number of CD8+ T cells differentiated in fetal thymic organ cultures of TAP1 or {beta}2-microglobulin-deficient mice when the expression of class I MHC was restored by adding a single peptide (15, 16). Likewise, class II MHC molecules bound with a dominant class II-associated invariant chain peptide (CLIP)3 or single E{alpha} (52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68) peptide (Ep) could select a number of {alpha}{beta}TCRs, suggesting that positive selection of some {alpha}{beta}TCRs may be promiscuous (17, 18, 19, 20). Moreover, {alpha}{beta}TCRs selected by a single MHC/peptide complex could recognize antigenic peptides that were different from the selecting peptide, implying that some of these receptors may engage distinct MHC/peptide ligands (21, 22, 23).

Peptide specificity of positive selection of T cells has been commonly studied using TCR transgenic mice in which all T cells can express the same TCR. Transgenic expression of TCR preserves its original specificity for antigenic peptide and sensitivity to negative selection (7, 24, 25, 26). However, whether transgenic expression conserves the TCR’s original requirements for positively selecting MHC/peptide complex is unknown. Indeed, thymic development of TCR transgenic T cells in a genuine thymic milieu can be manifested by highly enhanced or severely impaired positive selection (27, 28, 29, 30, 31). Since the TCR genes for transgenic mice are cloned from wild-type mice that express multiple MHC/peptide complexes, the natural, positively selecting MHC/peptide ligand(s) for a native TCR is not known and, therefore, its role in the selection of transgenic TCR could not be evaluated. In this study, we investigated the flexibility of positive selection of several transgenic TCRs originally selected in vivo in mice expressing one detectable class II MHC/peptide complex.

We cloned three TCRs selected in vivo on thymic epithelium expressing Ab molecules covalently bound with a single peptide (Ep), and specific for different peptides presented by Ab (19). These TCRs were expressed as transgenes using two different expression systems under the CD2 or TCR promoters (32, 33). We then followed their in vivo positive selection on thymic epithelium that expressed Ab bound with many or few endogenous peptides or covalently linked single peptides. Transgenic expression of each of these TCRs arrested the development of transgenic T cells toward the CD4+ lineage on the original, positively selecting thymic epithelium expressing the AbEp complex. However, one of the transgenic TCRs, specific for antigenic peptide with no sequence homology to Ep peptide, was efficiently selected on thymic epithelium expressing Ab bound with different arrays of self peptides or a covalently bound analogue of Ep. In contrast, transgenic TCRs specific for two different Ep analogues were not selected as CD4+ T cells in any of the tested thymic environments. Instead, transgenic T cells bearing these TCRs differentiated as CD8+ or CD4-CD8- T cells, similarly to misselected MHC class II-restricted transgenic TCRs (such as AND, DO11.10) that commit to the wrong lineage in the absence of the optimal selecting class II MHC/peptide ligand or coreceptor (34, 35, 36, 37, 38). These results demonstrate that the repertoire of TCRs selected by the AbEp complex contains TCRs with high or low specificity for the positively selecting MHC/peptide ligand, and indicate that transgenic expression of {alpha}{beta}TCR changes the original requirement for the positively selecting MHC/peptide ligand.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Animals

Mice expressing Ab covalently bound with the single peptide derived from E{alpha} (52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68) (Ep) were described previously (19). We have produced mice expressing covalently bound analogues of Ep (Ep58K and Ep63K) and pigeon cytochrome c-derived peptide PCC (43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58) (Pacholczyk, manuscript in preparation). All single Ab/peptide mice were crossed to invariant chain knockout mice (AbIi-) (kindly provided by E. Bikoff, Harvard Medical School, Boston, MA and R. Germain, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD) and mice deficient for wild-type Ab (kindly provided by D. Mathis, Harvard Medical School). The DM knockout mice were kindly provided by L. van Kaer (Vanderbilt University, Nashville, TN). C57BL/6 (Abwt), Abm12, and TCR{alpha}-chain knockout mice were purchased from The Jackson Laboratory (Bar Harbor, ME). All mice were housed under specific pathogen-free conditions in the animal care facility at the Medical College of Georgia (Augusta, GA). To generate chimeric mice, 8- to 12-wk-old recipient animals were lethally irradiated (1100 rad) and reconstituted on the same day with 5 x 106 fetal liver cells from Ab fetuses (day 15, gestational age). Alternatively, recipient mice were reconstituted with the bone marrow of adult mice treated with anti-Thy-1.2 mAb (H.O.13.4.9) and complement. Chimeras were used for experiments not earlier than 8 wk after reconstitution. At least three mice or chimeras of each type were analyzed.

Generation of Ag-specific T cell hybridomas

Hybridomas specific for E{alpha} (52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68) analogues and PCC were generated as described (22, 39). Briefly, single peptide mice expressing Ab covalently bound with peptide derived from the E{alpha} molecule (AbEpIi-) were irradiated and reconstituted with fetal liver cells from C57BL/6 mice. Chimeras were immunized with synthetic peptides Ep58K(ASFEAQKALANIAVDKA), Ep63K(ASFEAQGALANKAVDKA), and PCC(AEGFSYTDANKNKGIT) in CFA (2.5 mg/ml). CD4+ T cells from the draining lymph nodes were converted into T cell hybridomas, as described (39). The PCC-specific hybridoma responded better to the PCC(50V54A) analogue, and this peptide was then used as Ag in proliferation assays. Hybridomas were analyzed using flow cytometry for the expression of CD4 and TCR. Double-positive hybridomas were tested for peptide-specific response using a standard IL-2 release assay (40). In short, a T cell hybridoma (1 x 105) cell was stimulated in the presence or absence of a specific peptide using 5 x 105 irradiated Abwt splenocytes. After 24 h, supernatants were tested for the presence of IL-2 by measuring proliferation of IL-2-dependent cells (HT-2) using an MTT assay (Sigma, St.Louis, MO) (41).

Cloning TCRs from T cell hybridomas and generation of TCR transgenic mice

Total RNA was isolated using the Ultraspec RNA isolation system (Biotex, Edmonton, Canada) based on the guanidium thiocyanate method (42). The RNA was subjected to affinity chromatography on oligo(dT) resin (Qiagen, San Francisco, CA). Sequences of the TCR genes were obtained using two independent cloning strategies. We used V{alpha}- and V{beta}-specific primers to amplify and clone parts of the {alpha}- and {beta}-chains. Alternatively, we used a linker PCR method to clone V regions of the {alpha}- and {beta}-chains starting with the 5' untranslated sequences.

In the first approach, the first strand of the cDNA was synthesized with AMV reverse transcriptase (Promega, Madison, WI) and an oligo(dT) primer. Aliquots of the cDNA reaction were used in the PCR reaction with a collection of V{alpha}- or V{beta}-specific oligonucleotides as 5' primers and primers specific for {alpha} and {beta} (TCR-C{beta}3) C regions as 3' primers. We used modified linker PCR as the second approach to clone TCR genes (42). Using this method, we were able to obtain the sequences of V{alpha}- and V{beta}-chain transcripts starting with the 5' untranslated region. The two approaches used yielded the same results: that is, the {alpha}- and {beta}-chain clones isolated by amplification with V{alpha}- and V{beta}-specific primers had the identical complementarity-determining region 3 sequences as isolated by the linker PCR method. All hybridomas had nonproductive rearrangement of one of the {alpha} loci. The DNA sequences obtained by the linker PCR method contained the complete V{alpha} and V{beta} sequences, starting 5' from the start codon. The sequences obtained were used to search the GenBank database. The PCC(50V54A)-specific TCR is encoded by V{alpha}4.5-J{alpha}23/V{beta}8.1-D{beta}2-J{beta}2.6 genes, the Ep58K-specific receptor uses V{alpha}3.4-J{alpha}27/V{beta}3-D{beta}1-J{beta}1.2 genes, and the Ep63K-specific receptor uses V{alpha}2-J{alpha}26/V{beta}14-D{beta}2-J{beta}2.6 genes. Based on sequence information, we designed primers to amplify and clone the {alpha}- and {beta}-chains in TCR expression vectors pT and VA-hCD2 (kindly provided by D. Mathis and D. Kioussis, National Institute of Medical Research, London, U.K.). The PCC(50V54A)-specific TCR was cloned in both pT and VA-hCD2 cassettes. The Ep58K- and Ep63K-specific TCRs were cloned only into pT cassettes. The integrity of constructs was checked by transfection using a variant of the 5KC hybridoma deficient in TCR expression. Transfectants were analyzed by a stimulation assay with the respective antigenic peptides and by staining with mAb specific for the respective TCR V{alpha} (if available) and V{beta} segments (data not shown). All TCR transgenic mice were made by comicroinjection of the respective TCR{alpha} and TCR{beta} constructs into fertilized eggs of F1 (C57BL/6 x CBA/Ca) mice. Two founder mice were generated forPCC(VA), one for PCC(pT), three for Ep58K(pT), and two for Ep63K(pT) constructs. No significant differences in the phenotypes among the different mouse lines expressing the same transgenic TCRs were noticed. In particular, founder lines expressing a particular TCR transgene did not differ in the level of TCR expression on thymocyte populations. Selected founder mice were crossed at least four times with C57BL/6TCR{alpha}-/- mice. Mice used as bone marrow donors were TCR transgenics that expressed wild-type Ab and were deficient in the expression of endogenous TCR{alpha}-chain.

Flow cytometry analysis

mAbs specific for CD4, CD8, and different V{alpha} and V{beta} segments of TCRs were self-prepared or purchased from PharMingen (San Diego, CA). Standard staining procedures were used as previously described (39). Cells were analyzed using a FACSCalibur instrument (Becton Dickinson, San Jose, CA) and CellQuest software. Spleens were strained through nylon mesh. Erythrocytes were lysed by treatment with ammonium chloride solution. Cells were stained on ice with anti-CD45R (B220) Ab and with Y3P or YAe. Gating on forward and side scatter identified viable cells. Expression of total Ab or Ab bound to Ep peptide was determined on gated CD45R-positive cells.

Ag response of TCR transgenic cells

Proliferation of lymph node cells isolated from various chimeras was measured in response to Ag. Lymph node cells from transgenic mice and radiation chimeras reconstituted with bone marrow from PCC(VA) or PCC(pT) TCR{alpha}- C57BL/6 transgenic mice were used in proliferation assays. Cells were stimulated with the antigenic peptide PCC(50V54A) (50 µg/ml) presented by the wild-type Ab APCs. A total of 5 x 105 irradiated APCs was mixed with 0.75 x 105, 1.5 x 105, and 3 x 105 responder cells. Lymph node cells from Ep58K(pT) and Ep63K(pT) TCR{alpha}- transgenic mice and Ep58K(pT)TCR{alpha}-->AbEpIi- and Ep63K(pT)TCR{alpha}-->AbEpIi- radiation chimeras were stimulated with soluble antigenic peptides Ep58K and Ep63K, respectively, (50 µg/ml) that were presented by spleen cells expressing Ab and lacking class I MHC expression due to knockout of the {beta}2-microglobulin gene. In 96-well plate, 5 x 105 irradiated APCs were mixed with 1.25 x 105 and 2.5 x 105 responder cells. IgGVH (59–74) peptide was used as a negative control, and proliferation was measured after 3 days by the MTT assay (41).


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Selection and cloning of Ag-specific TCRs from CD4+ T cells positively selected in vivo by a single AbEp complex

We have followed the in vivo development of CD4+ T cells expressing transgenic TCRs that were originally positively selected on class II MHC (Ab) bound with the known peptide (Ep). In mice exclusively expressing the AbEp complex, more than two-thirds of TCRs on CD4+ T cells were found not tolerant to self peptides bound to Ab, which led to their profound negative selection upon exposure to wild-type Ab/peptide complexes (19, 39). In vivo studies of the development of CD4+ T cells expressing such TCRs would have to be limited to the original AbEpIi- mice, and their promiscuity or specificity for the selecting MHC/peptide ligand cannot be determined in mice expressing Ab bound with peptides different from Ep. Therefore, to isolate genes encoding TCRs tolerant to self peptides and Ab, we produced radiation chimeras by reconstituting lethally irradiated AbEpIi- mice with fetal liver cells from 15-day-old fetuses of C57BL/6 mice. In these chimeras, the TCR repertoire of CD4+ T cells was positively selected by radioresistant thymic epithelium expressing the AbEp complex and was purged of TCRs reactive with the natural set of self peptides by the donor’s APCs derived from fetal liver. Expression of donor wild-type Ab molecules in the periphery allowed us to prime CD4+ T cells positively selected on AbEp on thymic epithelium with antigenic peptides, and to establish CD4+ T cell hybridomas specific for antigenic peptides presented by Ab (39). To have a better representation of the repertoire originally positively selected by AbEp complex, we cloned TCR genes from three different CD4+ T cell hybridomas and used them to make TCR transgenic mice. All three hybridomas had the second TCR{alpha} locus nonfunctionally rearranged, so the TCR expressed on the surface had to mediate positive selection of the parental CD4+ T cell (Ignatowicz, Kraj, unpublished). All three hybridomas were also tolerant to covalent AbEp complex and Ab bound with self peptides.

The first hybridoma, 2.1.4, recognized the PCC (43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58) peptide or its analogue PCC(50V54A), which had enhanced binding and stimulatory properties over the original PCC peptide (43). The TCR cloned from this CD4+ T cell hybridoma was expressed in vivo using either the CD2 promoter (VA cassette) or genuine TCR promoters (pT{alpha}/pT{beta} cassettes) (32, 33). We refer to these two transgenic TCRs as PCC(VA) and PCC(pT).

Two other CD4+ T cell hybridomas that we selected as TCR gene donors expressed TCRs specific for two analogues of the Ep peptide that each had a single TCR contact residue changed (22, 44). Hybridoma 221.15 was specific for the Ep analogue with isoleucine replaced by lysine in position 63 (Ep63K). Another hybridoma, 123.1, was specific for the Ep analogue with glycine replaced by lysine in position 58 (Ep58K) (39). Both of these TCRs were expressed as transgenes using pT{alpha}/pT{beta} expression cassettes. We refer to these two transgenic TCRs as Ep63K(pT) and Ep58K(pT). The DNA sequences of TCRs isolated from the transgenic mice were confirmed by DNA sequencing to exclude a possibility of mutation. The progeny of founder mice for each transgenic TCR were backcrossed to TCR{alpha}-chain-deficient ({alpha}-) H-2b mice. Four selected mouse lines with exclusive expression of the respective transgenic TCRs were produced and used in all further studies.

Transgenic PCC(VA) and PCC(pT) TCRs are efficiently selected on Ab bound with different repertoires of self-derived peptides, some Ab/covalent peptide complexes, but are not positively selected by the original AbEp complex

We first analyzed two transgenic TCRs that recognized the PCC(50V54A) analogue. As shown in Fig. 1Go, the expression levels of the transgenic PCC(VA) or PCC(pT) TCRs on CD4+CD8+ and CD4+ subpopulations of thymocytes were slightly different from the expression level of endogenous TCRs in wild-type mice. The expression of the PCC(VA) TCR was higher then the expression of native TCRs on CD4+CD8+ thymocytes, while the same TCR cloned in the (pT) cassettes was expressed at lower levels. Moreover, thymocytes and peripheral CD4+ T cells partially down-regulated expression of the PCC(pT) TCR. This phenomenon was not associated with negative selection as tested by TUNEL assay, staining with annexin V, or thymus cellularity (data not shown). Noticeably, the PCC(VA) or PCC(pT) TCRs were efficiently positively selected by wild-type Ab/peptide complexes in the absence of AbEp complex, and isolated transgenic CD4+ T cells vigorously responded to antigenic peptide (shown later in Fig. 4Go, A and B). Positive selection of the PCC(VA)- or PCC(pT)-expressing thymocytes specifically depended on the presence of Ab molecules. Lethally irradiated recipient mice expressing AdEd (BALB/c) or AkEk (CBA/Ca) molecules or lacking Ab expression and which were reconstituted with the bone marrow from these TCR transgenic mice did not generate mature thymocytes (data not shown). Following these initial observations, we investigated the peptide specificity of positive selection of these two transgenic TCRs by reconstituting lethally irradiated mice expressing Ab molecules bound with different arrays of endogenous or covalently bound peptides with T cell-depleted, transgenic bone marrow.



View larger version (59K):
[in this window]
[in a new window]
  		FIGURE 1. Expression of PCC(VA) and PCC(pT) TCRs on thymocytes and peripheral lymph node cells. A, Thymocytes from C57BL/6 mice (left), PCC(VA) (middle), and PCC(pT) TCR{alpha}- transgenic mice (right) were stained for CD4 and CD8 expression. The total numbers of thymocytes in C57BL6, PCC(VA), and PCC(pT) TCR transgenic mice were respectively 73 x 106 ± 19, 68.1 x 106 ± 16.2, 76.5 x 106 ± 13.4. At least three mice of each kind were analyzed. B, TCR expression on gated double-negative CD4-CD8- (left), double-positive CD4+CD8+ (middle), and single-positive CD4+CD8- thymocytes (right) of PCC(VA) (– – – –), PCC(pT) TCR{alpha}- mice (·····), and C57BL/6 mice (). C, Peripheral lymph node cells of C57BL/6 mouse (left), PCC(VA) (middle), and PCC(pT) (left) TCR{alpha}- transgenic mice were stained for CD4 and V{beta}8 expression. Numbers indicate the percentage of different subpopulations of thymocytes or peripheral T cells.

 


View larger version (15K):
[in this window]
[in a new window]
  		FIGURE 4. Functional analysis of peripheral transgenic T cells isolated from PCC(VA), PCC(pT), Ep58K(pT), and Ep63K(pT) TCR{alpha}- transgenic mice or different radiation chimeras. x-axis represents cell number and y-axis represents OD570 nm reading. Filled symbols ({blacksquare}, •, {diamondsuit}, {blacktriangleup}) represent the responses to antigenic peptides. Open symbols ({square}, {circ}, {diamond}, {Delta}) refer to the responses to control peptide IgGVH (59–74). A, Proliferative response of transgenic T cells isolated from PCC(VA) TCR{alpha}- transgenic mouse ({blacksquare}, {square}), PCC(VA)TCR->AbEp58KIi- chimeras (•, {circ}), and PCC(VA)TCR->AbIi- ({diamondsuit}, {diamond}) chimeras. B, Proliferative response of transgenic T cells isolated from PCC(pT) TCR{alpha}- transgenic mouse ({blacksquare}, {square}), PCC(pT)TCR->AbEp58KIi- chimeras (•, {circ}), and PCC(pT)TCR->AbIi- chimeras ({diamondsuit}, {diamond}). C, Proliferative response of transgenic T cells isolated from Ep58K(pT) TCR{alpha}- transgenic mouse ({diamondsuit}, {diamond}), Ep63K(pT) TCR{alpha}- transgenic mouse (•, {circ}), Ep58K(pT) TCR{alpha}-->AbEpIi- chimeras ({blacksquare}, {square}), and 63K(pT) TCR{alpha}-->AbEpIi- ({blacktriangleup}, {triangleup}) chimeras.

 
As shown in the upper panel in Fig. 2GoA, no CD4+ transgenic T cells were found in the thymus and in the periphery of the original AbEpIi- mice lethally irradiated and reconstituted with transgenic bone marrow. Development of the PCC(VA) thymocytes was arrested at the CD4+CD8+ stage, and no negative selection was detected by TUNEL assay (data not shown). Similarly, thymocytes bearing the PCC(pT) TCR controlled by the genuine TCR regulatory elements were not positively selected by the original thymic epithelium expressing the AbEp complex (Fig. 2GoB). An interpretation that native CD4+ T cells expressing this TCR were originally selected in AbEpIi- chimeras by undetectable Ab/self-derived complexes rather than the AbEp complex could not explain why the same low-abundant peptides did not continue to positively select the PCC(VA) or PCC(pT) TCRs (45).



View larger version (31K):
[in this window]
[in a new window]
  		FIGURE 2. Flow cytometric analysis of thymocytes from recipient mice reconstituted with bone marrow from PCC(VA) and PCC(pT) TCR transgenic mice. Eight- to ten-week-old recipient mice were lethally irradiated and reconstituted i.v. with at least 5 x 106 bone marrow cells from mice expressing PCC(VA) or PCC(pT) TCRs crossed to TCR{alpha}- C57BL/6. Donor bone marrow was treated with anti-Thy-1.2 and complement. Panels on the left show thymocytes stained with anti-CD4 and anti-CD8 Abs, and panels on the right show peripheral lymph node cells stained with anti-CD4 and anti-V{beta}8 Ab. Bone marrow from PCC(VA) and PCC(pT) TCR transgenic mice was used to reconstitute the following recipient mice: A, B, AbEpIi-; C, Abm12; D, E, AbIi-; F, AbDM-. Numbers represent the percentage of different subpopulations of thymocytes or peripheral T cells. The numbers of cells recovered from thymuses were: A, 52.5 x 106 ± 28; B, 36.3 x 106 ± 13.1; C, 47.7 x 106 ± 3.8; D, 31.3 x 106 ± 13.1; E, 59.6 x 106 ± 29.6; F, 51.1 x 106 ± 23.6. Three mice in each group were analyzed.

 
In contrast, the PCC(VA)-bearing CD4+ T cells were positively selected in radiation chimeras that express, on thymic epithelium, a variant of Ab with an altered peptide-binding grove (Abm12) (Fig. 2GoC). The CD4+ T cells from Abm12 mice are not tolerant to APCs from Ab wild-type mice, and vice versa, due to the different array of self peptides bound to Ab vs Abm12 (46, 47, 48). This suggested that different self peptides might select the PCC(VA) TCR.

To test whether Ab molecules occupied with a more limited set of self peptides would support positive selection of the PCC(VA)- or PCC(pT)-expressing CD4+ T cells, we made radiation chimeras using invariant chain-deficient mice (AbIi-) as recipients. In these mice, peptides bound to low levels of Ab are distinct from peptides bound to Ab in wild-type mice (49, 50, 51). Nevertheless, the PCC(VA) TCR and PCC(pT) TCRs were positively selected by Ab/self peptide complexes expressed on thymic epithelium of AbIi- mice (Fig. 2Go, D and E). In contrast, the development of transgenic T cells was arrested at the CD4+CD8+ stage when bone marrow from PCC(VA) or PCC(pT) mice was used to reconstitute H2-DM knockout mice (AbDM-), in which the majority of Ab molecules is occupied with CLIP peptide (17, 18, 52) (Fig. 2GoF and data not shown). In conclusion, we found that, regardless of the expression system used, the {alpha}{beta}TCR expressed as a transgene is not positively selected by its original, positively selecting class II MHC/peptide ligand, but instead is selected on high or low levels of Ab bound with different endogenous peptides.

Since both TCRs tested above were not selected in the original AbEpIi- mice, we made new transgenic mice that express Ab covalently bound with two different variants of Ep. Each of these variants has a single amino acid mutation in the residues identified as {alpha}{beta}TCR contact residues. Glycine at position 58 and isoleucine at position 63 were substituted with lysine to produce Ep58K and Ep63K, respectively. We also made transgenic mice that express PCC (43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58) peptide covalently bound to Ab. This peptide has previously been found to have the lowest affinity to Ab molecules of all peptides tested in this study (22). We used mice expressing the PCC/Ab complex to determine whether low-abundant peptides that might have replaced the covalently linked peptide positively selected transgenic CD4+ T cells. None of the covalently bound Ep variants or PCC peptides were recognized by the original 2.1.4 T cell hybridoma. Transgenic mice expressing Ep variants or PCC covalently bound to Ab were separately bred to obtain mice without endogenous Ab and invariant chain (11, 53). These mice, which we refer to as AbEp58KIi-, AbEp63KIi-, and AbPCCIi- (Pacholczyk, manuscript in preparation), were then lethally irradiated and separately reconstituted with bone marrow from the PCC(VA) or PCC(pT) TCR transgenics. Development of the PCC(VA)- or PCC(pT)-bearing thymocytes was arrested at the double-positive stage in AbPCCIi- and AbEp63KIi- radiation chimeras reconstituted with bone marrow from the relevant TCR transgenic mouse (Fig. 3Go, A and B, and data not shown). In contrast, both PCC(VA) and PCC(pT) TCRs were positively selected on thymic epithelium expressing the AbEp58K complex (Fig. 3Go, C and D). The CD4+ T cells selected in AbEp58KIi- recipients repopulated the peripheral lymphoid organs and responded in vitro to antigenic peptide (Fig. 4Go, A and B).



View larger version (39K):
[in this window]
[in a new window]
  		FIGURE 3. Analysis of PCC(VA) or PCC(pT) TCR transgenic thymocytes and peripheral lymph node cells isolated from single peptide mice. Recipient mice used were: A, AbEp63KIi-; B, AbPCCIi-; C, D, AbEp58KIi-. These mice were reconstituted with bone marrow from PCC(VA) TCR{alpha}- (A, B, C) or PCC(pT) TCR{alpha}- (D) transgenic mice. Left panels, Show thymocytes stained for CD4 and CD8 expression. Right panels, Show expression of the V{beta}8 transgenic {beta}-chain and CD4 on peripheral lymph node cells. Numbers represent the percentage of different subpopulations of thymocytes or T cells. Total number of thymocytes were: A, 61.5 x 106 ± 21.2; B, 87.5 x 106 ± 24.7; C, 64.6 x 106 ± 22.2; D, 43.3 x 106 ± 13.8. Data represent analysis of at least three mice in each group.

 
Transgenic TCRs specific for analogues of Ep peptide are misselected as CD4-CD8- or CD8+ T cells in different thymic environments

Two transgenic TCRs specific for the Ep63K and Ep58K analogues were expressed in pT{alpha}/pT{beta} cassettes since this system provides genuine TCR regulatory sequences and because only quantitatively different outcomes of positive selection were recorded for previously analyzed PCC(VA) vs PCC(pT) transgenic T cells. As shown in Fig. 5Go, mice expressing wild-type Ab/peptide complexes and lacking endogenous TCR{alpha}-chain had higher expression levels of the Ep63K(pT) or Ep58K(pT) TCRs on some double-positive thymocytes, compared with the expression of native TCRs. A similar expression pattern of these two transgenic TCRs was a common feature found in five different founder lines (2 for Ep63K(pT) and 3 for Ep58K(pT)). Thymocytes bearing the Ep63K(pT) or Ep58K(pT) TCRs that developed in mice expressing wild-type Ab bound with self peptides differentiated toward CD8+ or CD4-CD8- subpopulations (Fig. 5Go). The Ep58K(pT) and Ep64K(pT) transgenic T cells proliferated in vitro in response to Ab and Ag, but showed no cytotoxic activity (Fig. 4GoC, and data not shown).



View larger version (44K):
[in this window]
[in a new window]
  		FIGURE 5. Expression of the Ep58K(pT) and Ep63K(pT) TCRs on thymocytes and peripheral lymph node cells. A, Thymocytes from Ep58K(pT) TCR{alpha}- mice (left), Ep63K(pT) TCR{alpha}- transgenic mice (right) were stained for CD4 and CD8 expression. B, TCR expression on gated double-positive CD4+CD8+ (left), and single-positive CD4-CD8+ thymocytes (right) of Ep58K(pT) (– · –) and Ep63K(pT) TCR{alpha}- (– · · –) and C57BL6 mice (). C, Peripheral lymph node cells of Ep58K(pT) (left) and Ep63K(pT) (right) TCR{alpha}- transgenic mice were stained for CD8 and transgenic V{beta} expression. The total number of thymocytes in Ep58K(pT) mice was 57 x 106 ± 21.5, and in Ep63K(pT) mice 56.3 x 106 ± 14.2. Three mice were analyzed in each group.

 
To investigate whether the original thymic epithelial cells expressing the AbEp complex are capable of reverting the lineage commitment of Ep63K(pT) and Ep58K(pT) TCR-expressing thymocytes, we lethally irradiated the original AbEpIi- mice and reconstituted them with transgenic bone marrow. Regardless of the genuine composition of the Ab bound with covalent Ep, we found no CD4+ T cells bearing a transgenic TCR in the original selecting environment. Instead, as in the wild-type mice, the transgenic T cells emerged from the thymus as CD4-CD8- or CD8+ T cells (Fig. 6Go, A and C).



View larger version (50K):
[in this window]
[in a new window]
  		FIGURE 6. Flow cytometric analysis of thymocytes (upper) and peripheral lymph nodes (lower) from recipient mice reconstituted with bone marrow from Ep58K(pT) and Ep63K(pT) TCR{alpha}- transgenic mice. A, Cells from AbEpIi- recipient mouse reconstituted with Ep58K(pT) TCR{alpha}- mouse bone marrow were stained with anti-CD4 and anti-CD8 Abs (upper) and anti-CD8, and anti-V{beta}3 (lower). B, Negative selection of Ep58K(pT) TCR on Ep58K peptide covalently bound to Ab. AbEp58KIi- mice were reconstituted with Ep58K(pT) TCR{alpha}- bone marrow, and cells were analyzed as above. C, Cells from AbEpIi- recipient mouse reconstituted with 63K(pT) TCR{alpha}- mouse bone marrow were stained with anti-CD4 and anti-CD8 mAbs (upper) and anti-CD8, anti-V{beta}14 Abs (lower). Total number of thymocytes was: A, 26.7 x 106 ± 6.1; B, 3.1 x 106 ± 2; C, 27.3 x 106 ± 8.8. Three mice were analyzed in each group.

 
To compensate for the elevated expression of TCR that may skew transgenic T cells toward the CD4- cells, we have seeded the transgenic bone marrow into mice that express less AbEp complex on thymic epithelium than homozygous AbEpIi- mice (Fig. 7Go). The T cells expressing the original TCRs specific for Ep63K and Ep58K were derived from chimeras homozygous for AbEp complex. In mice heterozygous for the Ab{beta}Ep transgene, AbEp expression on thymic epithelium was reduced by approximately 30% (assessed by comparing mean fluorescence intensities) in comparison with homozygous mice (data not shown). The expression of AbEp complex is diluted by expression of other Ab/self peptide complexes in mice that have endogenous Ab{beta}-chain, lack an invariant chain, and are transgenic for one copy of the Ab{beta}Ep chain (AbwtAbEp+/-Ii- mice) (Fig. 7Go). We have also crossed Ab{beta}Ep transgenic mice with H2-M-deficient mice to get AbCLIPAbEpDM- mice. In these mice, Abwt and transgenic Ab molecules are dominantly bound by CLIP peptide. The covalent Ep is cleaved in the presence of Ii, which results in further reduction of AbEp expression (Fig. 7Go). Finally, in mice that express the AbEp complex in the absence of endogenous Ab{beta}-chain, but in the presence of Ii, the expression of AbEp complex was the lowest of all mice tested (Fig. 7Go). All the mice expressing various levels of the AbEp complex were lethally irradiated and reconstituted with T cell-depleted bone marrow from either Ep63K(pT) or Ep58K(pT) transgenic mice. Regardless of the different amounts of the AbEp complex, the transgenic T cells differentiated as CD8+ and CD4-CD8- in all the mice described above (data not shown).



View larger version (25K):
[in this window]
[in a new window]
  		FIGURE 7. Expression of Ab and AbEp in different recipients reconstituted with bone marrow from Ep63K(pT) or Ep58K(pT) TCR transgenics. Spleen B cells (B220+) isolated from different recipient mice were stained with Y3P Ab specific for all Ab molecules (A) or with YAe Ab specific only for Ab bound to Ep peptide (B). A, Total level of Ab class II molecules expressed on splenic B cells in C57BL/6 mice (filled histogram), AbEp+/+Ii- homozygote (), AbEp+/-Ii- heterozygote (·····), AbCLIPAbEpDM- (– – – –), AbEp+/+Ii+ (– · – · –), and in AbwtAbEp+/-Ii- (– ·· –) recipient mice determined by staining with Y3P. B, The level of AbEp class II complex expressed on splenic B cells in C57BL/6 mice (filled histogram), AbEp+/+Ii- homozygote (), AbEp+/-Ii- heterozygote (·····), AbCLIPAbEpDM- (– – – –), AbEp+/+Ii+ (– · –), and in AbwtAbEp+/-Ii- (– ·· –) recipient mice determined by staining with YAe.

 
We also tested whether the Ep63K(pT) or Ep58K(pT) TCRs would be selected in vivo toward the CD4+ lineage by analogues of Ep covalently bound to Ab. The AbEp63KIi- and AbEp58KIi- mice were irradiated and reconstituted with T cell-depleted bone marrow from the relevant TCR transgenics. In the AbEp63KIi- irradiated host, both transgenic thymocytes matured again as CD8+ or CD4-CD8- T cells, while in chimeras expressing the AbEp58K complex on thymic epithelium, 58K(pT) TCR-bearing thymocytes were negatively selected (Fig. 6GoB).

Differentiation of the transgenic Ep63K(pT) and Ep58K(pT) TCRs also progressed toward CD4- cells in other tested chimeras, e.g., AbIi-, AbDM-, Abm12, similarly to other misselected, class II MHC-restricted transgenic TCRs (data not shown) (34). Importantly, the down-regulation of CD4 on transgenic T cells bearing the Ep63K(pT) TCR was not a result of the lack of tolerance to wild-type Ab/peptides expressed on bone marrow-derived thymic APCs. Bone marrow from mice expressing this TCR and devoid of Ab(Ep63K(pT)Ab-) was used to reconstitute lethally irradiated hosts expressing Ab bound with self peptides or covalent Ep, and transgenic thymocytes still differentiated only as CD4- T cells (data not shown).

Transgenic T cells are not positively selected on the thymic epithelium expressing AbEp complex in mixed bone marrow chimeras

Positive selection of T cells expressing transgenic TCRs depends on the availability of the selecting MHC/peptide ligand. To determine whether the block in positive selection of our transgenic TCRs results from competition for a very small amount of the selecting Ab/peptide ligand, we have made mixed bone marrow chimeras. For that purpose, we reconstituted lethally irradiated AbEpIi- mice with 7 x 106 bone marrow cells derived as follows: 80% from TCR{alpha} knockout, 10% from PCC(VA) (or Ep63K(pT)), and 10% from B6.PL donors. In this experiment, the majority of CD4+CD8+ thymocytes did not express a functional TCR, and only 5–20% expressed either the transgenic TCR (and Thy-1.2) or endogenous TCRs (and Thy-1.1). As shown in Fig. 8Go, the reduced frequency of thymocytes bearing rearranged transgenic TCRs did not restore their positive selection. Based on this result, we concluded that the lack of selection of bulk transgenic TCRs does not result from competition for the limiting amount of the low-abundant MHC/peptide ligand.



View larger version (33K):
[in this window]
[in a new window]
  		FIGURE 8. Transgenic T cells expressing PCC(VA) or Ep63K(pT) are not selected in AbEpIi- recipients reconstituted with mixed bone marrow. The lethally irradiated AbEpIi- mice have been reconstituted with 7 x 106 mixed bone marrow cells (80% TCR{alpha}-/-, 10% of either PCC(VA) or Ep63K(pT) (all expressing Thy-1.2), and 10% of B6. PL expressing Thy-1.1). Three chimeras of each type were analyzed 8 wk after reconstitution. Thymus reconstitution with TCR+ cells varied between 5 and 20% of total thymocytes. Expression of the transgenic receptor is shown vs Thy-1.1 on gated TCR+ T cells in the thymus (left) and in the periphery (right). A, TCR-positive thymocytes and lymph node cells from PCC(VA) mixed bone marrow chimera stained with anti-V{beta}8 and anti-Thy-1.1 Abs. B, TCR-positive thymocytes and lymph node cells from Ep63K(pT) mixed bone marrow chimera stained with anti-V{alpha}2 and anti-Thy-1.1 Abs.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
To our knowledge, this is the first study that investigated the development of T cells expressing TCRs originally selected in vivo on a defined class II MHC/peptide complex. In this system, all T cells expressed transgenic TCRs positively selected by thymic epithelium expressing AbEp complex, and all detectable class II MHC molecules were preloaded with the selecting peptide. One may have expected that our model would constitute an optimal selecting niche (54, 55, 56). Instead, T cells expressing three different transgenic TCRs originally positively selected on thymic epithelium with class II MHC molecules covalently bound with one peptide were unable to follow the ontogeny of the same native TCRs in the genuine thymic environment. The lack of positive selection of three transgenic TCRs in the original thymic milieu does not contradict the results of the experiments of others in which the selection of many transgenic TCRs cloned from wild-type mice followed the normal development of T cells. Instead, our results suggest that selection of the transgenic TCR in wild-type mice depends on: 1) TCR flexibility for the selecting MHC/peptide ligand; and 2) complexity of self peptides bound to MHC. In wild-type mice bearing a transgenic TCR, these two conditions often compensate for different patterns and levels of expression of the transgenic TCR, which results in the anticipated differentiation of transgenic T cells. In mice coexpressing a transgenic TCR and MHC occupied with covalent peptide, the thymocytes have no choice of an alternative selecting MHC/peptide ligand, and the development is altered. Therefore, we postulate that transgenic expression of the TCR may affect its original requirements for the positively selecting MHC/peptide ligand(s?).

Several possible rationales can be offered to resolve the lack of selection of the transgenic TCRs on the AbEp complex. One may argue that the TCRs investigated in this study were selected on contaminating peptides that replaced some of the covalently attached Ep, or wild-type self peptides derived from donor bone marrow (45, 57). However, selection of the transgenic TCRs was followed in Abwt->AbEpIi- chimeras, that is, in the same environment that still contains the contaminating or bone marrow-derived peptides. The experiments conducted to date did not detect the presence of endogenous peptides in the original AbEpIi- mice (58, 59). The development of the majority of CD4+ thymocytes was blocked in AbEpIi- fetal thymic organ culture with YAe Ab specific for the AbEp complex (Pacholczyk, manuscript in preparation). Lowering the precursor frequency in experiments with mixed bone marrow chimeras could not restore positive selection of transgenic T cells. Together these results suggest that the lack of selection of the transgenic cells is not due to the limited availability of MHC/peptide ligand or growth factors (55, 56). Conceivably, TCRs positively selected on one highly abundant MHC/peptide ligand may represent abnormal CD4+ T cells. It has been shown previously that T cells isolated from single peptide mice have a normal surface phenotype and respond to antigenic peptides in an MHC-restricted manner (39). Also, the T cells expressing transgenic TCRs specifically respond to their cognate antigenic peptides presented by Ab. We have also defined the selecting MHC backgrounds for the PCC-specific TCR and show that transgenic CD4+ cells remained functional. In conclusion, we did not find evidence that T cells selected on one MHC/peptide ligand differ from T cells present in normal mice. Therefore, we favor the explanation that transgenic expression of an {alpha}{beta}TCR frequently requires the use of an alternative peptide bound to the selecting MHC haplotype. This is often accomplished in mice expressing MHC bound with a wild-type repertoire of peptides, but not in mice expressing a single class II MHC/peptide complex.

In several in vitro studies, chemically synthesized or naturally derived peptides bound to MHC positively selected a defined transgenic TCR in fetal thymic organ cultures (5, 6, 60, 61). However, when some of these peptides were genetically manipulated to bind to the selecting MHC molecules in vivo, the same transgenic TCRs were not positively selected (62, 63). Failure of the in vivo induced, positive selection of the transgenic TCR by the in vitro defined, positively selecting peptide indicates that manipulation of any of the TCR/MHC/peptide components may alter the final outcome of the selection processes. These results support the hypothesis that positive selection depends on the subtle avidity of the involved TCR/MHC/peptide complexes (64). Possibly, natively expressed TCRs adjust to the quantity of the selecting MHC/peptide ligand differently than the transgenic TCRs, which may explain the difficulty of achieving positive selection of the transgenic TCR on the original selecting MHC/peptide ligand.

Multiple lines of evidence indicate that recognition of MHC by developing thymocytes influences the T cell lineage commitment (28, 65, 66, 67). However, the ability of the TCR to engage class I or II MHC is not the only factor that determines coreceptor expression on mature T cells. Transgenic T cells expressing AND or DO11.10 TCRs differentiated as CD8+ or CD4-CD8- T cells in the absence of the optimal selecting MHC/peptide ligand (34, 68). Ligation of CD3 on C5 TCR transgenic thymocytes in fetal thymic organ cultures by anti-CD3 F(ab')2 reagents or an antagonistic peptide led to the differentiation of mature CD8+ thymocytes, irrespective of the MHC class II restriction specificity of this TCR. The tyrosine phosphorylation patterns in these thymocytes resembled patterns found in mature CD8+ T cells stimulated with antagonistic peptides (37). Hence, it has been proposed that the relative balance of signals delivered by TCR engagement and by p56lck activation is responsible for lineage commitment (69). The phenotype of Ep58K(pT) and Ep63K(pT) transgenic cells indicates that these cells did not receive an optimal selecting signal and were selected with the mismatched CD8 coreceptor. Recently, it was shown that such class II MHC-restricted TCR transgenic cells with the aberrant expression of a coreceptor methylate the CD8 gene, down-regulate its surface expression, and gradually convert to CD4-CD8- T cells that poorly survive in the periphery (38).

If transgenic expression unintentionally tests TCR flexibility for positive selection, our results show that the repertoire of TCRs selected on the single class II MHC/peptide complex consists of TCRs promiscuous or specific for the Ab and selecting peptide. The PCC-specific TCR was selected in different thymic environments, which correlated with its ability to bind unrelated MHC/peptide ligands (such as PCC v Ep). Positive selection of this transgenic TCR in mice different in the complexity of peptides bound to Ab, such as C57BL/6, Abm12, AbIi-, and AbEp58KIi-, suggests that this receptor is selected by different peptides bound to Ab rather than a single peptide ubiquitously present in all these mice. On the other hand, the only peptides we identified that were recognized by Ep58K(pT) and Ep63K(pT) TCRs were Ep or its close analogues. We hypothesize that these TCRs may have narrow requirements for positive selection. Various levels of AbEp ligand did not select both of these TCRs. In addition, these TCRs were not able to adopt an alternative, positively selecting ligand when tested in the same set of mice as the PCC-specific receptors. Therefore, we postulate that the TCR repertoire consists of TCRs specific and promiscuous in their choice of the positively selecting MHC/peptide ligand. The crystallographic data showing that the peptide contribution to the interaction between TCR and MHC/peptide complex varies support this conclusion (70, 71, 72).


   Acknowledgments
 
We thank Drs. P. Kisielow, P. Jensen, B. Chmielowski, and A. Mellor for helpful discussion, and R. Markowitz for editing the manuscript. We also thank H. Ignatowicz and G. Pacholczyk for their help in producing transgenic mice, and Drs. D. Mathis, C. Benoist, E. Bikoff, R. Germain, L. Glimcher, C. Janeway, D. Kioussis, and L. van Kaer for their generous gifts of knockout mice, DNA constructs, and Abs. All work involving animals was conducted under protocols approved by the Animal Care and Use Committee at Medical College of Georgia.


   Footnotes
 
1 This work was supported by National Institutes of Health basic research grants (AI41145-01A1 and HD36302-02) to L.I. Back

2 Address correspondence and reprint requests to Dr. Leszek Ignatowicz, Institute of Molecular Medicine and Genetics, Medical College of Georgia, Augusta, GA 30912-2600. Back

3 Abbreviations used in this paper: CLIP, class II-associated invariant chain peptide; PCC, pigeon cytochrome c-derived peptide. Back

Received for publication June 27, 2000. Accepted for publication November 21, 2000.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Merkenschlager, M., D. Graf, M. Lovatt, U. Bommhardt, R. Zamoyska, A. G. Fisher. 1997. How many thymocytes audition for selection?. J. Exp. Med. 186:1149.[Abstract/Free Full Text]
  2. Zerrahn, J., W. Held, D. H. Raulet. 1997. The MHC reactivity of the T cell repertoire prior to positive and negative selection. Cell 88:627.[Medline]
  3. Jameson, S. C., K. A. Hogquist, M. J. Bevan. 1995. Positive selection of thymocytes. Annu. Rev. Immunol. 13:93.[Medline]
  4. Allen, P.. 1994. Peptides in positive selection: a delicate balance. Cell 76:593.[Medline]
  5. Hogquist, K. A., S. C. Jameson, W. R. Heath, J. L. Howard, M. J. Bevan, F. R. Carbone. 1994. T cell receptor antagonist peptides induce positive selection. Cell 76:17.[Medline]
  6. Ashton-Rickardt, P. G., A. Bandeira, J. R. Delaney, L. Van Kaer, H.-P. Pircher, R. M. Zinkernagel, S. Tonegawa. 1994. Evidence for a differential avidity model of T cell selection in the thymus. Cell 76:651.[Medline]
  7. Kisielow, P., H. Bluthmann, U. D. Staerz, M. Steinmetz, H. von Boehmer. 1988. Tolerance in T-cell-receptor transgenic mice involves deletion of nonmature CD4+8+ thymocytes. Nature 333:742.[Medline]
  8. Kappler, J. W., N. Roehm, P. Marrack. 1987. T cell tolerance by clonal elimination in the thymus. Cell 49:273.[Medline]
  9. Surh, C. D., J. Sprent. 1994. T-cell apoptosis detected in situ during positive and negative selection in the thymus. Nature 372:100.[Medline]
  10. Kaer, L., P. G. Ashton-Rickardt, H. L. Ploegh, S. Tonegawa. 1992. TAP1 mutant mice are deficient in antigen presentation, surface class molecules, and CD4-8+ cells. Cell 71:1205.[Medline]
  11. Bikoff, E. K., L. Y. Huang, V. Episkopou, J. van Meerwijk, R. N. Germain, E. J. Robertson. 1993. Defective major histocompatibility complex class II assembly, transport, peptide acquisition, and CD4+ T cell selection in mice lacking invariant chain expression. J. Exp. Med. 177:1699.[Abstract/Free Full Text]
  12. Kenty, G., W. D. Martin, L. Van Kaer, E. K. Bikoff. 1998. MHC class II expression in double mutant mice lacking invariant chain and DM functions. J. Immunol. 160:606.[Abstract/Free Full Text]
  13. Elliott, E., J. Drake, S. Amigorena, J. Elsmore, P. Webster, I. Mellman, R. Flavell. 1994. The invariant chain is required for intracellular transport and function of major histocompatibility complex class II molecules. J. Exp. Med. 179:681.[Abstract/Free Full Text]
  14. Shachar, I., E. A. Elliott, B. Chasnof, I. S. Grewal, R. A. Flavell. 1995. Reconstitution of invariant chain function in transgenic mice in vivo by individual p31 and p41 isoforms. Immunity 3:373.[Medline]
  15. Ashton-Rickardt, P. G., L. V. Kaer, T. N. M. Schumacher, H. L. Ploegh, S. Tonegawa. 1993. Peptide contributes to the specificity of positive selection of CD8+ T cells in the thymus. Cell 73:1041.[Medline]
  16. Pawlowski, T., M. D. Singleton, D. Y. Loh, R. Berg, U. D. Staerz. 1996. Permissive recognition during positive selection. Eur. J. Immunol. 26:851.[Medline]
  17. Martin, W. D., G. G. Hicks, H. E. Ruley, L. v. Kaer. 1996. H2-M mutant mice are deficient in the peptide loading of class II molecules, antigen presentation, and T cell repertoire selection. Cell 84:543.[Medline]
  18. Miyazaki, T., P. Wolf, S. Tourne, C. Waltzinger, A. Dierich, N. Barois, H. Ploegh, C. Benoiste, D. Mathis. 1996. Mice lacking H2-M complexes, enigmatic elements of the MHC class II peptide-loading pathway. Cell 84:531.[Medline]
  19. Ignatowicz, L., J. W. Kappler, P. Marrack. 1996. The repertoire of T cells shaped by a single MHC/peptide ligand. Cell 84:521.[Medline]
  20. Fukui, Y., T. Ishimoto, M. Utsuyama, T. Gyotoku, T. Koga, K. Nakao, K. Hirokawa, M. Katsuki, T. Sasazuki. 1997. Positive and negative CD4+ thymocytes selection by a single MHC class II/peptide ligand affected by its expression level in the thymus. Immunity 6:401.[Medline]
  21. Tourne, S., T. Miyazaki, A. Oxenius, L. Klein, T. Fehr, B. Kyewski, C. Benoist, D. Mathis. 1997. Selection of a broad repertoire of CD4+ T cells in H-2Ma0/0 mice. Immunity 7:187.[Medline]
  22. Ignatowicz, L., W. Rees, R. Pacholczyk, H. Ignatowicz, E. Kushnir, J. Kappler, P. Marrack. 1997. T cells can be activated by peptides that are unrelated in sequence to their selecting peptide. Immunity 7:179.[Medline]
  23. Surh, C. D., D. Lee, W. Fung-Leung, L. Karlsson, J. Sprent. 1997. Thymic selection by a single MHC/peptide ligand produces a semidiverse repertoire of CD4+ T cells. Immunity 7:209.[Medline]
  24. Sha, W., C. Nelson, R. Newberry, D. Kranz, J. Russell, D. Loh. 1988. Positive and negative selection of an antigen receptor on T cells in transgenic mice. Nature 336:73.[Medline]
  25. Murphy, K. M., A. B. Heimberger, D. Loh. 1990. Induction by antigen of intrathymic apoptosis of CD4+ CD8+ TCRlo thymocytes in vivo. Science 250:1720.[Abstract/Free Full Text]
  26. Swat, W., L. Ignatowicz, H. Von Boehmer, P. Kisielow. 1991. Clonal deletion of immature CD4+8+ thymocytes in suspension culture by extrathymic antigen-presenting cells. Nature 351:150.[Medline]
  27. Kelly, K. A., H. Pircher, H. von Boehmer, M. M. Davis, R. Scollay. 1993. Regulation of T cell production in T cell receptor transgenic mice. Eur. J. Immunol. 23:1922.[Medline]
  28. Kaye, J., M. L. Hsu, M. E. Sauron, S. C. Jameson, N. R. Gascoigne, S. M. Hedrick. 1989. Selective development of CD4+ T cells in transgenic mice expressing a class II MHC-restricted antigen receptor. Nature 341:746.[Medline]
  29. Bogen, B., L. Gleditsch, S. Weiss, Z. Dembic. 1992. Weak positive selection of transgenic T cell receptor-bearing thymocytes: importance of major histocompatibility complex class II, T cell receptor and CD4 surface molecule densities. Eur. J. Immunol. 3:703.
  30. Kouskoff, V., A. S. Korganow, V. Duchatelle, C. Degott, C. Benoist, D. Mathis. 1996. Organ-specific disease provoked by systemic autoimmunity. Cell 87:811.[Medline]
  31. Kersh, G. J., D. L. Donermeyer, K. E. Frederick, J. M. White, B. L. Hsu, P. M. Allen. 1998. TCR transgenic mice in which usage of transgenic {alpha}- and {beta}-chains is highly dependent on the level of selecting ligand. J. Immunol. 161:585.[Abstract/Free Full Text]
  32. Zhumabekov, T., P. Corbella, M. Tolaini, D. Kioussis. 1995. Improved version of a human CD2 minigene based vector for T cell-specific expression in transgenic mice. J. Immunol. Methods 185:133.[Medline]
  33. Kouskoff, V., K. Signorelli, C. Benoist, D. Mathis. 1995. Cassette vectors directing expression of T cell receptor genes in transgenic mice. J. Immunol. Methods 180:273.[Medline]
  34. Matechak, E. O., N. Killeen, S. M. Hedrick, B. J. Fowlkes. 1996. MHC class II-specific T cells can develop in the CD8 lineage when CD4 is absent. Immunity 4:337.[Medline]
  35. Kirberg, J., A. Baron, S. Jakob, A. Rolink, K. Karjalainen, H. von Boehmer. 1994. Thymic selection of CD8+ single positive cells with a class II major histocompatibility complex-restricted receptor. J. Exp. Med. 180:25.[Abstract/Free Full Text]
  36. Liu, C. P., D. Parker, J. Kappler, P. Marrack. 1997. Selection of antigen-specific T cells by a single IEk peptide combination. J. Exp. Med. 186:1441.[Abstract/Free Full Text]
  37. Volkmann, A., T. Barthlott, S. Weiss, R. Frank, B. Stockinger. 1998. Antagonist peptide selects thymocytes expressing a class II major histocompatibility complex-restricted T cell receptor into the CD8 lineage. J. Exp. Med. 188:1083.[Abstract/Free Full Text]
  38. Pestano, G. A., Y. Zhou, L. A. Trimbl, J. Daley, G. F. Weber, H. Cantor. 1999. Inactivation of misselected CD8 T cells by CD8 gene methylation and cell death. Science 284:1187.[Abstract/Free Full Text]
  39. Chmielowski, B., P. Muranski, L. Ignatowicz. 1999. In the normal repertoire of CD4+ T cells, a single class II MHC/peptide complex positively selects TCRs with various antigen specificities. J. Immunol. 162:95.[Abstract/Free Full Text]
  40. Kappler, J. W., B. Skidmore, J. White, P. Marrack. 1981. Antigen-inducible, H-2-restricted, interleukin-2-producing T cell hybridomas: lack of independent antigen and H-2 recognition. J. Exp. Med. 153:1198.[Abstract/Free Full Text]
  41. Mosmann, T.. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65:55.[Medline]
  42. Kraj, P., D. F. Friedman, F. Stevenson, L. E. Silberstein. 1995. Evidence for the overexpression of the VH4-34 (VH4.21) Ig gene segment in the normal adult human peripheral blood B cell repertoire. J. Immunol. 154:6406.[Abstract]
  43. Itoh, Y., K. Ogasawara, K. Takami, T. Gotohda, H. Naruse, R. A. Good, K. Onoé. 1994. Determination of amino acids on agretopes of pigeon cytochrome c-related peptides specifically bound to I-A allelic products. Eur. J. Immunol. 24:76.[Medline]
  44. Gyotoku, T., Y. Fukui, T. Sasazuki. 1998. An endogenously processed self peptide and the corresponding exogenous peptide bound to the same MHC class II molecule could be distinct ligands for TCR with different kinetic stability. Eur. J. Immunol. 28:4050.[Medline]
  45. Barton, G. M., A. Y. Rudensky. 1999. Requirement for diverse, low-abundance peptides in positive selection of T cells. Science 283:67.[Abstract/Free Full Text]
  46. Bill, J., J. Yage, V. B. Appel, J. White, G. Horn, H. A. Erlich, E. Palmer. 1989. Molecular genetic analysis of 178 I-Abm12-reactive T cells. J. Exp. Med. 169:115.[Abstract/Free Full Text]
  47. Murphy, D. B., D. Lo, S. Rath, R. L. Brinster, R. A. Flavell, A. Slanetz, C. A. J. Janeway. 1989. A novel MHC class II epitope expressed in thymic medulla but not on cortex. Nature 338:765.[Medline]
  48. Humblet, C., A. Y. Rudensky, B. Kyewski. 1994. Presentation and intercellular transfer of self antigen within the thymic microenvironment: expression of the E {alpha} peptide-I-Ab complex by isolated thymic stromal cells. Int. Immunol. 6:1949.[Abstract/Free Full Text]
  49. Viville, S., J. Neefjes, V. Lotteau, A. Dierich, M. Lemeur, H. Ploegh, C. Benoist, D. Mathis. 1993. Mice lacking the MHC class II-associated invariant chain. Cell 72:635.[Medline]
  50. Bodmer, H., S. Viville, C. Benoist, D. Mathis. 1994. Diversity of endogenous epitopes bound to MHC class II molecules limited by invariant chain. Science 263:1284.[Abstract/Free Full Text]
  51. Tourne, S., C. Nakano, C. Benoist, D. Mathis. 1995. The influence of invariant chain on the positive selection of single T cell receptor specificities. Eur. J. Immunol. 25:1851.[Medline]
  52. Fung-Leung, W., C. D. Surh, M. Liljedahl, J. Pang, D. Leturcq, P. A. Peterson, S. R. Webb, L. Karlsson. 1996. Antigen presentation and T cell development in H2-M-deficient mice. Science 271:1278.[Abstract]
  53. Cosgrove, D., D. Gray, A. Dierich, J. Kaufman, M. Lemeur, C. Benoist, D. Mathis. 1991. Mice lacking MHC class II molecules. Cell 66:1051.[Medline]
  54. Merkenschlager, M., C. Benoist, D. Mathis. 1994. Evidence for a single-niche model of positive selection. Proc. Natl. Acad. Sci. USA 91:11694.[Abstract/Free Full Text]
  55. Merkenschlager, M., A. G. Fisher. 1994. In vitro construction of graded thymus chimeras. J. Immunol. Methods 171:177.[Medline]
  56. Huesmann, M., B. Scott, P. Kisielow, H. von Boehmer. 1991. Kinetics and efficacy of positive selection in the thymus of normal and T cell receptor transgenic mice. Cell 66:533.[Medline]
  57. Bix, M., D. Raulet. 1992. Inefficient positive selection of T cells directed by haematopoietic cells. Nature 359:330.[Medline]
  58. Grubin, C. G., S. Kovats, P. deRoos, A. Y. Rudensky. 1997. Deficient positive selection of CD4 T cells in mice displaying altered repertoires of MHC class II-bound self-peptides. Immunity 7:197.[Medline]
  59. Wilson, N. A., P. Wolf, H. Ploegh, L. Ignatowicz, J. Kappler, P. Marrack. 1998. Invariant chain can bind MHC class II at a site other than the peptide binding groove. J. Immunol. 161:4777.[Abstract/Free Full Text]
  60. Hogquist, K. A., A. J. Tomlinson, W. C. Kieper, M. A. McGargill, M. C. Hart, S. Naylor, S. C. Jameson. 1997. Identification of a naturally occurring ligand for thymic positive selection. Immunity 6:389.[Medline]
  61. Hu, Q., C. R. Bazemore Walker, C. Girao, J. T. Opferman, J. Sun, J. Shabanowitz, D. F. Hunt, P. G. Ashton-Rickardt. 1997. Specific recognition of thymic self-peptides induces the positive selection of cytotoxic T lymphocytes. Immunity 7:221.[Medline]
  62. Levelt, C. N., E. Mizoguchi, X. Huang, R. Zacks, A. K. Bhan, S. Tonegawa. 1998. Inhibition of intrathymic T cell development by expression of a transgenic antagonist peptide. Proc. Natl. Acad. Sci. USA 95:14349.[Abstract/Free Full Text]
  63. Goldrath, A., M. J. Bevan. 1999. Low-affinity ligands for the TCR drive proliferation of mature CD8+ T cells in lymphopenic hosts. Immunity 11:183.[Medline]
  64. Ashton-Rickardt, P. G., S. Tonegawa. 1994. A differential-avidity model for T-cell selection. Immunol. Today 15:362.[Medline]
  65. Teh, H. S., P. Kisielow, B. Scott, H. Kishi, Y. Uematsu, H. Bluthmann, H. von Boehmer. 1988. Thymic major histocompatibility complex antigens and the {alpha}{beta} T-cell receptor determine the CD4/CD8 phenotype of T cells. Nature 335:229.[Medline]
  66. Sha, W. C., C. A. Nelson, R. D. Newberry, D. M. Kranz, J. H. Russell, D. Y. Loh. 1988. Selective expression of an antigen receptor on CD8-bearing T lymphocytes in transgenic mice. Nature 335:271.[Medline]
  67. Berg, L. J., A. M. Pullen, B. Fazekas de St. Groth, D. Mathis, C. Benoist, M. M. Davis. 1989. Antigen/MHC-specific T cells are preferentially exported from the thymus in the presence of their MHC ligand. Cell 58:1035.[Medline]
  68. Liu, C. P., J. W. Kappler, P. Marrack. 1996. Thymocytes can become mature T cells without passing through the CD4+ CD8+, double-positive stage. J. Exp. Med. 184:1619.[Abstract/Free Full Text]
  69. Basson, M. A., U. Bommhardt, P. J. Mee, V. L. Tybulewicz, R. Zamoyska. 1998. Molecular requirements for lineage commitment in the thymus: antibody-mediated receptor engagements reveal a central role for lck in lineage decisions. Immunol. Rev. 165:181.[Medline]
  70. Hausmann, S., W. E. Biddison, K. J. Smith, Y. H. Ding, D. N. Garboczi, U. Utz, D. C. Wiley, K. W. Wucherpfennig. 1999. Peptide recognition by two HLA-A2/Tax11–19-specific T cell clones in relationship to their MHC/peptide/TCR crystal structures. J. Immunol. 162:5389.[Abstract/Free Full Text]
  71. Ding, Y. H., K. J. Smith, D. N. Garboczi, U. Utz, W. E. Biddison, D. C. Wiley. 1998. Two human T cell receptors bind in a similar diagonal mode to the HLA-A2/Tax peptide complex using different TCR amino acids. Immunity 4:403.
  72. Reinherz, E. L., T. Kemin, L. Tang, P. Kern, J. Liu, Y. Xiong, H. Hussey, R. E. Smolyar, A. Hare, B. R. Zhang, et al 1999. The crystal structure of a T cell receptor in complex with peptide and MHC class II. Science 286:1913.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 J. Immunol.Home page
M. Kuczma, I. Pawlikowska, M. Kopij, R. Podolsky, G. A. Rempala, and P. Kraj
TCR Repertoire and Foxp3 Expression Define Functionally Distinct Subsets of CD4+ Regulatory T Cells
J. Immunol., September 1, 2009; 183(5): 3118 - 3129.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
J. J. MARCHALONIS, S. KAVERI, S. LACROIX-DESMAZES, and M. D. KAZATCHKINE
Natural recognition repertoire and the evolutionary emergence of the combinatorial immune system
FASEB J, June 1, 2002; 16(8): 842 - 848.
[Abstract] [Full Text] [PDF]

Home page
 JEMHome page
P. Kraj, R. Pacholczyk, H. Ignatowicz, P. Kisielow, P. Jensen, and L. Ignatowicz
Positive Selection of Cd4+ T Cells Is Induced in Vivo by Agonist and Inhibited by Antagonist Peptides
J. Exp. Med., August 20, 2001; 194(4): 407 - 416.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kraj, P.
Right arrow Articles by Ignatowicz, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kraj, P.
Right arrow Articles by Ignatowicz, L.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS